Johnson & Johnson
JNJ
Performance
About Johnson & Johnson
Johnson & Johnson is a global healthcare company focused on medicines, medical devices, and consumer health products. The company operates in therapeutics including oncology, immunology, neuroscience, and cardiopulmonary areas, and develops innovative medical technologies across cardiovascular, orthopaedics, surgery, and vision. Through its Innovative Medicine and MedTech divisions, J&J aims to address complex diseases with science-driven approaches and patient-centered care worldwide. Headquartered with a strong presence in multiple regions, the company emphasizes scientific advancement, patient outcomes, and global health impact.
Recent News
Hologic CEO Steve MacMillan to Retire After Go-Private Deal
The Capacity Crunch in Biopharma Is a Location Problem
Wall Street Slides as S&P 500 Dips 0.1% and Brent Falls to $95 Amid U.S.-Iran Cease‑fire Talks
Diagonal Banks Another $125M for ‘Clustering’ Antibody Drugs
Isomorphic Labs Raises $2.1 B to Expand AI-Driven Drug Discovery Platform
Martin Marietta Appoints Chris Samborski as COO Amid Strategic Expansion
AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules
This Week in European MedTech and HealthTech: 10th April 2026
Dizal Breaks New Ground for EGFR Drugs in Lung Cancer
Iridius Raises $8.6M Seed Round to Build Compliance-by-Design AI Platform for Regulated Enterprise Workflows
FDA Delays Decision on Sanofi's Subcutaneous Sarclisa
Parabilis Heads Biotech Fundraising Frenzy With $305M to Advance Cancer Drug
Is Pharma Missing the Boat on Diagnostics?
Nanobiotix Secures FDA Acceptance of Protocol Amendment to Accelerate Phase 3 NANORAY-312 Trial
Eli Lilly Raises $9 Billion in Record Investment‑Grade Bond Offering to Finance Acquisitions
CFOs On the Move: Week Ending April 17
Hawkesbury Conducts Surgery with J&J Robot
STAT+: Johnson & Johnson Advances IBD Therapy, Despite Trial Miss
FDA Sets Feb. 1 Launch Date for PreCheck Pilot To Strengthen Domestic Supply Chain
Tuneable Peptide Biotech Parabilis Files IPO
Stock Market Today: Dow Rises, Nasdaq Leads On Inflation Data; Credo Makes Another Big Move (Live Coverage)
The 5 Largest IPOs in Biopharma History
Amid Iran War, Companies Look to Extend a Record Profit Run by Raising Prices
What Johnson & Johnson Earnings Signal for Healthcare ETFs
Brepocitinib Approval May Be ‘Highlight of the Derm-Rheum World’
Alphabet's Isomorphic Labs Raises $2.1 Billion to Scale AI Drug Discovery Toward Clinical Trials
Ocugen Shares Fall, Despite Positive Eye Disorder Trial
The Rise of Trispecific Antibodies: Biopharma’s Next Big Bet After Bispecifics
NAM Launches Second Change Maker Accelerators to Boost Health System Wellbeing
Defending the Disclosure Ecosystem: The Essential Role of Shareholder Proposals and Regulation S-K
JPM26: Protagonist Has a $400M Decision To Make. It’s a No-Brainer
Can an LSD Candidate Do for Anxiety What Spravato Did for Depression?
Top 20 Fastest Growing Pharma & Biotech Companies in the Americas for 2026
20 Future Swiss HealthTech and MedTech Leaders
Ghent, Porto, Wroclaw: Future European HealthTech and MedTech Hubs
PharmaShots Quarterly Outlook: The Forces Reshaping Biopharma in Q1 2026
Johnson & Johnson Brushes Off MFN Impact, Sees Strong Growth for 2026
BMS Brings the Buzz Around Late-Stage Readouts Amid a So-So Q1
Morningstar: US Equities Trade 5% Below Fair Value After April Rally
FDA Warns Public About Johnson & Johnson Heart Pump Controllers After Patient Death
Pfizer’s Oncology Sales Poised for Growth Ahead of Q1 Earnings
Violet Light Filtering IOL Shows Tolerance to Induced Astigmatism
Stryker Closes Amplitude Vascular Acquisition
Congress Reintroduces Bill to Block ‘Texas Two‑Step’ Bankruptcy Tactic
Earnings Week Ahead: JNJ, NFLX, TSM, GS, C, JPM, BAC, PEP, and More
J&J Lifts 2026 Sales Outlook to $100 B, Defying Pricing Headwinds
Pfizer's Oncology Portfolio Targets Growth Ahead of May 5 Earnings
Top 10 Most Popular Drug Hunter Reviews of 2025
Earnings Playbook: JPMorgan Chase and Netflix Kick Off the Reporting Season
Novartis Antimalarial Clears Key WHO Review to Get the Combo Drug to Babies